NO883306D0 - Farmasoeytisk aktive konjugater med forbedret bindingsspesifisitet for kroppsvev. - Google Patents

Farmasoeytisk aktive konjugater med forbedret bindingsspesifisitet for kroppsvev.

Info

Publication number
NO883306D0
NO883306D0 NO1988883306A NO883306A NO883306D0 NO 883306 D0 NO883306 D0 NO 883306D0 NO 1988883306 A NO1988883306 A NO 1988883306A NO 883306 A NO883306 A NO 883306A NO 883306 D0 NO883306 D0 NO 883306D0
Authority
NO
Norway
Prior art keywords
pct
binding specificity
pharmasoyytic
specific binding
improved body
Prior art date
Application number
NO1988883306A
Other languages
English (en)
Other versions
NO177526C (no
NO177526B (no
NO883306L (no
Inventor
Robert Albert Brown
Original Assignee
Central Blood Lab Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Central Blood Lab Authority filed Critical Central Blood Lab Authority
Publication of NO883306D0 publication Critical patent/NO883306D0/no
Publication of NO883306L publication Critical patent/NO883306L/no
Publication of NO177526B publication Critical patent/NO177526B/no
Publication of NO177526C publication Critical patent/NO177526C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
NO883306A 1986-11-27 1988-07-26 Fremgangsmåte for fremstilling av farmasöytisk aktive konjugater NO177526C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868628398A GB8628398D0 (en) 1986-11-27 1986-11-27 Pharmaceutically-active conjugates
PCT/GB1987/000854 WO1988003810A1 (en) 1986-11-27 1987-11-27 Pharmaceutically active conjugates having improved body tissue binding specificity

Publications (4)

Publication Number Publication Date
NO883306D0 true NO883306D0 (no) 1988-07-26
NO883306L NO883306L (no) 1988-07-26
NO177526B NO177526B (no) 1995-06-26
NO177526C NO177526C (no) 1995-10-04

Family

ID=10608055

Family Applications (1)

Application Number Title Priority Date Filing Date
NO883306A NO177526C (no) 1986-11-27 1988-07-26 Fremgangsmåte for fremstilling av farmasöytisk aktive konjugater

Country Status (10)

Country Link
US (1) US5151412A (no)
EP (1) EP0333740B1 (no)
JP (1) JP2721830B2 (no)
AT (1) ATE68977T1 (no)
AU (1) AU610104B2 (no)
DE (1) DE3774279D1 (no)
DK (1) DK168693B1 (no)
GB (1) GB8628398D0 (no)
NO (1) NO177526C (no)
WO (1) WO1988003810A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0340573A3 (de) * 1988-04-30 1990-05-30 BASF Aktiengesellschaft Neue Proteine, ihre Herstellung und Verwendung
US4892826A (en) * 1988-10-11 1990-01-09 Abbott Laboratories Process for the preparation of urokinase derivatives
WO1990006767A1 (en) * 1988-12-20 1990-06-28 La Jolla Cancer Research Foundation Polypeptide-polymer conjugates active in wound healing
US5654267A (en) * 1988-12-20 1997-08-05 La Jolla Cancer Research Center Cooperative combinations of ligands contained within a matrix
US5316934A (en) * 1989-06-13 1994-05-31 Nippon Soda Co., Ltd. Effective thrombosis mediated by human prourokinase-like polypeptides with increased binding affinity for thrombosis
US5013726A (en) * 1989-09-12 1991-05-07 Ivy Jeffery W External analgesic lotion containing active ingredients of methyl salicylate and camphor and menthol and method of making such lotion
US5124320A (en) * 1989-09-12 1992-06-23 Ivy Jeffery W An external analgesic lotion containing active ingredients of camphor and menthol and method of making such lotion
GB9023149D0 (en) * 1990-10-24 1990-12-05 British Bio Technology Proteins and nucleic acids
GB9101183D0 (en) * 1991-01-18 1991-02-27 Univ London Depot formulations
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
ES2123514T3 (es) * 1991-07-31 1999-01-16 Antex Biolog Inc Conjugados con receptor, destinados a dirigir farmacos y otros agentes.
JP2829405B2 (ja) * 1991-10-14 1998-11-25 寳酒造株式会社 機能性ポリペプチド
CN1091315A (zh) * 1992-10-08 1994-08-31 E·R·斯奎布父子公司 血纤维蛋白封闭剂组合物及其使用方法
US5591719A (en) * 1992-12-10 1997-01-07 Regents Of The University Of Minnesota Method for treating acute and chronic inflammatory disorders using polypeptides with fibronectin activity
DE4242736A1 (de) 1992-12-17 1994-06-23 Behringwerke Ag Synthetische Peptide, Antikörper dagegen und ihre Verwendung
WO1994016085A2 (en) * 1992-12-30 1994-07-21 Zymogenetics, Inc. Hybrid proteins having cross-linking and tissue-binding activities
WO1994017097A1 (en) * 1993-01-19 1994-08-04 Regents Of The University Of Minnesota Synthetic fibronectin fragments as inhibitors of retroviral infections
US5821074A (en) * 1993-12-21 1998-10-13 Abbott Laboratories Method and compositions for enhancing aminolevulinic acid dehydratase assay
AU702976B2 (en) * 1996-05-03 1999-03-11 Roger S. Cubicciotti Prodrug compositions and drug delivery methods using synthetic receptors
CA2315702A1 (en) * 1997-12-24 1999-07-08 Immunex Corporation V196 dna and polypeptides
NZ510497A (en) * 1998-08-21 2003-09-26 Immunex Corp Human IL-1 epsilon DNA and polypeptides
IN190822B (no) * 1998-12-24 2003-08-23 Council Scient Ind Res
US7678767B2 (en) * 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US7553810B2 (en) 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
WO2008036763A2 (en) * 2006-09-20 2008-03-27 Pneumrx, Inc. Tissue adhesive compositions and methods thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541435A (en) * 1975-02-04 1979-02-28 Searle & Co Immunological materials
GB2116979B (en) * 1982-02-25 1985-05-15 Ward Page Faulk Conjugates of proteins with anti-tumour agents
AR241654A1 (es) * 1982-05-05 1992-10-30 Genentech Inc Procedimiento para producir activador de plasminogeno de tejido humano.
US4589881A (en) * 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
JPS59134732A (ja) * 1983-01-21 1984-08-02 Green Cross Corp:The フイブロネクチン・生理活性物質複合体の製造法
JPS60226819A (ja) * 1984-04-25 1985-11-12 Green Cross Corp:The フイブロネクチン複合体
WO1986001720A1 (en) * 1984-09-13 1986-03-27 Cytogen Corporation Antibody therapeutic agent conjugates
US4587122A (en) * 1985-04-23 1986-05-06 The Green Cross Corporation Fibronectin-dextran-drug complex and method of preparation thereof

Also Published As

Publication number Publication date
JP2721830B2 (ja) 1998-03-04
EP0333740A1 (en) 1989-09-27
US5151412A (en) 1992-09-29
EP0333740B1 (en) 1991-10-30
GB8628398D0 (en) 1986-12-31
DK168693B1 (da) 1994-05-24
DK420988D0 (da) 1988-07-27
WO1988003810A1 (en) 1988-06-02
ATE68977T1 (de) 1991-11-15
DK420988A (da) 1988-07-27
NO177526C (no) 1995-10-04
NO177526B (no) 1995-06-26
AU8277387A (en) 1988-06-16
AU610104B2 (en) 1991-05-16
DE3774279D1 (de) 1991-12-05
NO883306L (no) 1988-07-26
JPH02501305A (ja) 1990-05-10

Similar Documents

Publication Publication Date Title
NO883306L (no) Farmasoeytisk aktive konjugater med forbedret bindingsspesifisitet for kroppsvev.
ATE324119T1 (de) Verwendung von saccharid-konjugaten
ATE165395T1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
NO20002957D0 (no) Behandling med anti-ErbB2-antistoffer
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
KR890701107A (ko) 알쯔하이머 병 치료용 화합물들
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
DE69010840D1 (de) Sterile chirurgische Nadel-Nähfaden-Zusammensetzung.
DE69625157D1 (de) Behandlung des typ ii-deabetes mellitus mit amylinagonisten
UY25263A1 (es) 6-derivados sustitutivos del ácido micofenólico.-
HUT56133A (en) Process for treating viral infections with functional derivatives of icam-1 intercellular adhesion molecule
DE68905000T2 (de) Zusammensetzung fuer die behandlung von fasern.
GB9603507D0 (en) Antibody variants
PL335140A1 (en) Therapeutic agent for treating lymphatic system carcinomas
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
DE69013999T2 (de) Siliconkautschukzusammensetzung zur Behandlung von Faserstrukturen.
DE3782214T2 (de) Mittel zur behandlung des scheidenmilieus.
DE69014666D1 (de) Abgabe von cytotoxischen Mitteln.
MY124071A (en) Treatment of viral disease in swine
ATE215084T1 (de) Imidazopyridin-azolidinone
ATE317021T1 (de) Antisense modulierung von lfa-3
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
KR900012622A (ko) 피부질환치료 조성물
RU96123360A (ru) Способ лечения сепсиса у новорожденных